These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22789768)

  • 1. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
    Karnon J
    Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic valuation of improved process plant decision support technology.
    White DC
    ISA Trans; 2007 Jun; 46(3):437-42. PubMed ID: 17434170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling.
    Spiegelhalter DJ; Best NG
    Stat Med; 2003 Dec; 22(23):3687-709. PubMed ID: 14652869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
    Fletcher C; Chuang-Stein C; Paget MA; Reid C; Hawkins N
    Pharm Stat; 2014; 13(4):265-74. PubMed ID: 24931490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regarding probabilistic analysis and computationally expensive models: necessary and required?
    Caro JJ; Getsios D; Möller J
    Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scenario drafting to anticipate future developments in technology assessment.
    Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
    BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of cost effectiveness in technology evaluation.
    Valk PE
    Q J Nucl Med; 2000 Jun; 44(2):197-203. PubMed ID: 10967629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economics and health technology assessment: perspectives from Australia and New Zealand.
    Streat S; Munn S
    Crit Care Clin; 2012 Jan; 28(1):125-33, vii. PubMed ID: 22123104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.